Medifast Third Quarter 2024 Earnings: Beats Expectations

In This Article:

Medifast (NYSE:MED) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$140.2m (down 41% from 3Q 2023).

  • Net income: US$1.13m (down 95% from 3Q 2023).

  • Profit margin: 0.8% (down from 9.8% in 3Q 2023). The decrease in margin was driven by lower revenue.

  • EPS: US$0.10 (down from US$2.12 in 3Q 2023).

earnings-and-revenue-history
NYSE:MED Earnings and Revenue History November 6th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medifast Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Personal Products industry in the US are expected to grow by 5.3%.

Performance of the American Personal Products industry.

The company's shares are up 10% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Medifast (1 is significant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Waiting for permission
Allow microphone access to enable voice search

Try again.